Forbes June 26, 2024
Sharon Edelson

Ozempic and Wegovy are having an unintended but not entirely unpredictable effect on the apparel industry. Impact Analytics, an AI-based planning and forecasting company, found that the GLP-1 drugs, which are typically prescribed for diabetes but are used by millions for weight loss, are driving down sizes in department and specialty stores. And the issue has implications all along the supply chain.

“It’s something that retailers need to monitor,” Impact Analytics founder and CEO Prashant Agrawal said. “It’s a sustainability issue. We can’t make things that won’t get used.”

The Impact Analytics report connects the dots between Ozempic and Wegovy use and clothing sizes and cites the effect of diminishing clothing measurements on retail profit margins.

“The slimming down of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Provider, Retailer
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups
AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More

Share This Article